This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Barta SK , Xue X , Wang D , Lee JY , Kaplan LD , Ribera JM , Oriol A , Spina M , Tirelli U , Boue F , Wilson WH , Wyen C , Dunleavy K , Noy A , Sparano JA
A new prognostic score for AIDS-related lymphomas in the rituximab-era
Haematologica. 2014 Nov;99(11) :1731-7
PMID: 25150257 URL: http://www.ncbi.nlm.nih.gov/pubmed/25150257
AbstractWhile the International Prognostic Index is commonly used to predict outcomes in immunocompetent patients with aggressive B-cell non-Hodgkin lymphomas, HIV-infection is an important competing risk for death in patients with AIDS-related lymphomas. We investigated whether a newly created prognostic score (AIDS-related lymphoma International Prognostic Index) could better assess risk of death in patients with AIDS-related lymphomas. We randomly divided a dataset of 487 patients newly diagnosed with AIDS-related lymphomas and treated with rituximab-containing chemoimmunotherapy into a training (n=244) and validation (n=243) set. We examined the association of HIV-related and other known risk factors with overall survival in both sets independently. We defined a new score (AIDS-related lymphoma International Prognostic Index) by assigning weights to each significant predictor [age-adjusted International Prognostic Index, extranodal sites, HIV-score (composed of CD4 count, viral load, and prior history of AIDS)] with three risk categories similar to the age-adjusted International Prognostic Index (low, intermediate and high risk). We compared the prognostic value for overall survival between AIDS-related lymphoma International Prognostic Index and age-adjusted International Prognostic Index in the validation set and found that the AIDS-related lymphoma International Prognostic Index performed significantly better in predicting risk of death than the age-adjusted International Prognostic Index (P=0.004) and better discriminated risk of death between each risk category (P=0.015 vs. P=0.13). Twenty-eight percent of patients were defined as low risk by the ARL-IPI and had an estimated 5-year overall survival (OS) of 78% (52% intermediate risk, 5-year OS 60%; 20% high risk, 5-year OS 50%).
NotesBarta, Stefan K Xue, Xiaonan Wang, Dan Lee, Jeannette Y Kaplan, Lawrence D Ribera, Josep-Maria Oriol, Albert Spina, Michele Tirelli, Umberto Boue, Francois Wilson, Wyndham H Wyen, Christoph Dunleavy, Kieron Noy, Ariela Sparano, Joseph A ENG KL2 RR025749/RR/NCRR NIH HHS/ UL1 RR025750/RR/NCRR NIH HHS/ U01CA121947/CA/NCI NIH HHS/ K12CA132783-03/CA/NCI NIH HHS/ TL1 RR025748/RR/NCRR NIH HHS/ UL1 TR001073/TR/NCATS NIH HHS/ K12 CA132783/CA/NCI NIH HHS/ P30 CA013330/CA/NCI NIH HHS/ U01 CA121947/CA/NCI NIH HHS/ Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Italy 2014/08/26 06:00 Haematologica. 2014 Nov;99(11):1731-7. doi: 10.3324/haematol.2014.111112. Epub 2014 Aug 22.